Squamous Cell Carcinoma Of The Head And Neck – Epidemiology – Mature Markets Data
DRG Epidemiology's coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of squamous cell carcinoma of the head and neck for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the world.
DRG Epidemiology's squamous cell carcinoma of the head and neck forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with squamous cell carcinoma of the head and neck per year?
- How will improvements in survival change the number of people living with a diagnosis of squamous cell carcinoma of the head and neck?
- How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for squamous cell carcinoma of the head and neck?
- Of all people diagnosed with squamous cell carcinoma of the head and neck, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of squamous cell carcinoma of the head and neck over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.
Note: Coverage may vary by country.
Table of contents
- Squamous Cell Carcinoma Of The Head And Neck - Epidemiology - Mature Markets Data
- Introduction
- Updates 2018
- Key Findings
- Incidence of Squamous Cell Carcinoma of the Head and Neck per 100,000 per Year Among People of All Ages in 2017 and 2037ttttttttt
- Patient Flow Diagram Nasopharyngeal Squamous cell carcinoma in 2017
- Patient Flow Diagram Non-nasopharyngeal Squamous cell carcinoma in 2017
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Squamous Cell Carcinoma of the Head and Neck over the Next 20 Yearsttttttttt
- Number of Incident Cases of Squamous Cell Carcinoma of the Head and Neck Avoided Over the Period 2017-2037 Across the Countries Under Study Owing to Trends in Risktttttttt
- Analysis of the Incident Cases of Squamous Cell Carcinoma of Head and Neck in 2017 by Primary Site Subtypettttttttt
- Epidemiology Data
- Methods
- Diagnosed Incident cases of Squamous Cell Carcinoma of the Head and Neck
- Stage Distribution of Squamous Cell Carcinoma of the Head and Neck
- Diagnosed Prevalent Cases of Squamous Cell Carcinoma of the Head and Neck
- Recurrent Incident Cases of Squamous Cell Carcinoma of the Head and Neck
- HPV and EBV Status
- Drug-Treatable Populations of Squamous Cell Carcinoma of the Head and Neck
- Drug-Treated Populations of Squamous Cell Carcinoma of Head and Neck
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Squamous Cell Carcinoma of the Head and Neck
- Studies Excluded from the Analysis of Squamous Cell Carcinoma of the Head and Neck
- Risk/Protective Factors
- Risk/Protective Factors for Squamous Cell Carcinoma of the Head and Neck
- Bibliography
- Bibliography
- Literature Review
- Introduction
Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.